First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2010-09-22 07:06:02Open Document File Size: 1,89 MBShare Result on FacebookCityGeneva / Nevirapine / Efavirenz / /CompanyABC / TRG Technical Reference Group / /ContinentAfrica / /CountrySwitzerland / / /FacilityAFB AIDS AUC / DMPA depot / Baseline laboratory / / /IndustryTermtherapy of HIV / health services / therapy for treatment failure / HIV care / Treatment of AIDS / therapy for HIV / energy / /MedicalConditionHIV infection / severe HIV disease / TB / acute and chronic toxicities / HIV / established HIV infection / XDR / HIV infections / AIDS / HIV/AIDS / HIV-associated clinical disease / tuberculosis / /MedicalTreatmentAntiretroviral therapy / directly observed therapy / highly active antiretroviral therapy / HAART / drug therapy / /OrganizationWorld Health Organization Department of HIV/AIDS ANTIRETROVIRAL ThERApy fOR hIV INfEcTION IN INfANTs ANd chILdREN / United States Agency for International Development / World Health Organization / United Nations / United Nations International Children's Emergency Fund / Federal Trade Commission / European Union / UNAIDS / Centers for Disease Control and Prevention / /PersonELISA ART / / /PositionExecutive / RT / /ProductBAL / efavirenz / zidovudine / tenofovir disoproxil fumarate / medroxyprogesterone acetate / nevirapine / INH / abacavir / lamivudine / didanosine / isoniazid / HIVResNet Global HIV Drug / stavudine / /ProgrammingLanguageEC / /URLwww.who.int/hiv / /SocialTag |